It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Monkeypox viral infection is an emerging threat and a major concern for the human population. The lack of drug molecules to treat this disease may worsen the problem. Identifying potential drug targets can significantly improve the process of developing potent drug molecules for treating monkeypox. The proteins responsible for viral replication are attractive drug targets. Identifying potential inhibitors from known drug molecules that target these proteins can be key to finding a cure for monkeypox. In this work, two viral proteins, DNA-dependent RNA polymerase (DdRp) and viral core cysteine proteinase, were considered as potential drug targets. Sixteen antibiotic drugs from the tetracycline class were screened against both viral proteins through high-throughput virtual screening. These tetracycline class of antibiotic drugs have the ability to inhibit bacterial protein synthesis, which makes these antibiotics drugs a prominent candidate for drug repurposing. Based on the screening result obtained against DdRp, top two compounds, namely Tigecycline and Eravacycline with docking scores of − 8.88 and − 7.87 kcal/mol, respectively, were selected for further analysis. Omadacycline and minocycline, with docking scores of − 10.60 and − 7.51 kcal/mol, are the top two compounds obtained after screening proteinase with the drug library. These compounds, along with reference compounds GTP for DdRp and tecovirimat for proteinase, were used to form protein–ligand complexes, followed by their evaluation through a 300 ns molecular dynamic simulation. The MM/GBSA binding free energy calculation and principal components analysis of these selected complexes were also conducted for understanding the dynamic stability and binding affinity of these compounds with respective target proteins. Overall, this study demonstrates the repurposing of tetracycline-derived drugs as a therapeutic solution for monkeypox viral infection.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 King Abdulaziz University, Special Infectious Agents Unit-BSL3, King Fahd Medical Research Center, Jeddah, Saudi Arabia (GRID:grid.412125.1) (ISNI:0000 0001 0619 1117); King Abdulaziz University, Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, Jeddah, Saudi Arabia (GRID:grid.412125.1) (ISNI:0000 0001 0619 1117)
2 King Abdulaziz University, Special Infectious Agents Unit-BSL3, King Fahd Medical Research Center, Jeddah, Saudi Arabia (GRID:grid.412125.1) (ISNI:0000 0001 0619 1117); King Abdulaziz University, Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, Rabigh, Saudi Arabia (GRID:grid.412125.1) (ISNI:0000 0001 0619 1117)
3 King Abdulaziz University, Special Infectious Agents Unit-BSL3, King Fahd Medical Research Center, Jeddah, Saudi Arabia (GRID:grid.412125.1) (ISNI:0000 0001 0619 1117); King Abdulaziz University, Biochemistry Department, Faculty of Sciences, Jeddah, Saudi Arabia (GRID:grid.412125.1) (ISNI:0000 0001 0619 1117)
4 King Abdulaziz University, Special Infectious Agents Unit-BSL3, King Fahd Medical Research Center, Jeddah, Saudi Arabia (GRID:grid.412125.1) (ISNI:0000 0001 0619 1117); Taibah University, Department of Medical Laboratory Technology, College of Applied Medical Sciences, Madinah, Saudi Arabia (GRID:grid.412892.4) (ISNI:0000 0004 1754 9358)
5 Sharda University, Department of Life Science, School of Basic Science and Research, Greater Noida, India (GRID:grid.412552.5) (ISNI:0000 0004 1764 278X)
6 Quanta Calculus, Computational Chemistry and Drug Discovery Division, Greater Noida, India (GRID:grid.412552.5)
7 Quanta Calculus, Bioinformatics Research Division, Greater Noida, India (GRID:grid.412552.5); Saveetha University, Center for Global Health Research, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Chennai, India (GRID:grid.412431.1) (ISNI:0000 0004 0444 045X)